Seeking Alpha

  BioCryst Pharmaceuticals, Inc. - NASDAQ

11/26/2014, 8:07 AM ET
  • Roy Manning III | Send Message 7 May 2012

    BCRX has sold off alot. I would consider it a buy now. News on a Gout drug partner or their Hep C. patent could push the stock higher.
      BCRX vs. ETF Alternatives
      Company Description
      Biocryst Pharmaceuticals Inc. is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include Peramivir, BCX4161, Forodesine and Ulodesine, among others.
      Sector: Healthcare
      Industry: Biotechnology
      Country: United States